PMV Pharma plans Q1 2027 rezatapopt application

PMV reports completed Phase 2 monotherapy enrollment and plans to submit an NDA for accelerated approval in the first quarter of 2027.

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. appointed Dr. Matthew Eckler to its board on October 1, 2026, with a term ending at the 2029 Annual Meeting of Stockholders. As a non-employee director, he is entitled to $40,000 in annual cash compensation, plus additional cash compensation for committee service. He received an initial stock option award for 84,000 shares, made on the first trading date on or after his appointment; PMV expects to grant an annual option to purchase 42,000 shares effective on each annual meeting date.

Enrollment is complete in the Phase 2 monotherapy portion of the PYNNACLE trial. PMV plans to submit a New Drug Application for accelerated approval of rezatapopt in the first quarter of 2027 for platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation. The FDA granted Fast Track designation for locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for TP53 Y220C-positive ovarian, fallopian tube and primary peritoneal cancers.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Annual director cash compensation: $40,000 per year Initial stock option award: 84,000 shares Annual option: 42,000 shares +2 more

5 metrics

Annual director cash compensation $40,000 per year For service on the board

Initial stock option award 84,000 shares Made on the first trading date on or after the appointment date

Annual option 42,000 shares Expected on the date of each annual meeting of stockholders

Planned NDA submission First quarter of 2027 For accelerated approval of rezatapopt

Board term 2029 Annual Meeting of Stockholders Dr. Eckler's term expires at this meeting

Key Terms

New Drug Application, Fast Track designation, Orphan Drug Designation, p53 reactivator, +1 more

5 terms

New Drug Application regulatory

"submit a New Drug Application for accelerated approval"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

Fast Track designation regulatory

"granted Fast Track designation to rezatapopt"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

Orphan Drug Designation regulatory

"Orphan Drug Designation for the treatment of TP53 Y220C positive ovarian cancer"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

p53 reactivator medical

"a first-in-class, small molecule, p53 reactivator"

platinum-resistant/refractory ovarian cancer medical

"patients with platinum-resistant/refractory ovarian cancer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What compensation will PMVP director Matthew Eckler receive?

Dr. Eckler is entitled to $40,000 in annual cash compensation, plus additional cash compensation for committee service, and received an initial stock option award for 84,000 shares. PMV expects to grant an annual option to purchase 42,000 shares effective on the date of each annual meeting of stockholders.

When does PMV plan to submit an NDA for rezatapopt?

PMV plans to submit a New Drug Application for accelerated approval in the first quarter of 2027. The application is planned for rezatapopt in platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 09:00 AM Accepted by SEC EDGAR 10/05/2026 - 09:00 AM Learn about SEC filing dates

false 0001699382 0001699382 2026-10-01 2026-10-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2026

PMV Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39539		46-3218129
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
400 Alexander Park Drive,
Suite 301
Princeton, NJ				08540
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (609) 642-6670

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		PMVP		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Appointment of New Director

On October 1, 2026 (the “Appointment Date”), Dr. Matthew Eckler was appointed to the board of directors (the “Board”) of PMV Pharmaceuticals, Inc. (the “Company”). Dr. Eckler will serve as a director with a term of office expiring at the Company’s 2029 Annual Meeting of Stockholders. Dr. Eckler, age 42, has served as a Principal at Samsara BioCapital, LLC, a venture capital and private equity firm, since May 2025. Prior to that, Dr. Eckler served as a healthcare investor at ArrowMark Partners, an investment management firm, from May 2021 to May 2025. Dr. Eckler received his B.S. in Biology from the University of North Carolina at Chapel Hill, his Ph.D. in Molecular Biology at the University of California, Santa Cruz and completed his postdoctoral fellowship in Neuroscience at the University of California, San Diego.

In accordance with the Company’s Outside Director Compensation Policy (the “Director Compensation Policy”), Dr. Eckler is eligible to participate in the Company’s standard compensation arrangements for non-employee directors which consists of cash and equity compensation for service on the Board. Pursuant to the Director Compensation Policy, Dr. Eckler is entitled to $40,000 in annual cash compensation for service on the Board with additional cash compensation payable for committee service. In addition, pursuant to the Director Compensation Policy, Dr. Eckler was granted an initial stock option award for 84,000 shares, which was made on the first trading date on or after the Appointment Date. Dr. Eckler is expected to be granted additional equity awards consistent with the terms of the Director Compensation Policy, including an annual option to purchase 42,000 shares, effective on the date of each annual meeting of the stockholders.

There are no arrangements or understandings between Dr. Eckler and any other persons pursuant to which Dr. Eckler was appointed a director of the Company, and there are no family relationships between Dr. Eckler and any director or executive officer of the Company.

The Company has entered into its standard form of indemnification agreement with Dr. Eckler, a copy of which is filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-248627) on September 4, 2020. Other than the indemnification agreement, Dr. Eckler has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor are any such transactions currently proposed.

Item 7.01. Regulation FD Disclosure.

On October 5, 2026, the Company issued a press release announcing Dr. Eckler’s appointment to the Board. The full text of this press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01 and Exhibit 99.1 hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference to such filing.

Item 9.01. Financial Statements and Exhibits.

(d)  Exhibits.

Exhibit No.		Description
99.1		Press Release issued by PMV Pharmaceuticals, Inc., dated October 5, 2026.
104		Cover Page Interactive Date File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				PMV PHARMACEUTICALS, INC.
Date: October 5, 2026				By:		/s/ Michael Carulli
						Michael Carulli
						Chief Financial Officer (Principal Financial and Accounting Officer)

Exhibit 99.1

PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors

Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research

Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027

PRINCETON, N.J., October 5, 2026 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced the appointment of Matt Eckler, Ph.D., to its Board of Directors (the “Board”). Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets and scientific research in molecular biology and neuroscience.

“Matt brings deep understanding of the biotechnology sector, including extensive healthcare investment experience,” said Laurie Stelzer, Chair of the Board. “We look forward to his strategic insight and contributions as we advance rezatapopt toward potential commercialization and position PMV Pharma for continued growth and success.”

Dr. Eckler joins the Board following completion of enrollment in the Phase 2 monotherapy portion of the ongoing PYNNACLE Phase 2 pivotal clinical trial and as the Company prepares to submit a New Drug Application (NDA) for accelerated approval for rezatapopt in patients with platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation in the first quarter of 2027.

Rezatapopt is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

“I am pleased to join PMV Pharma’s Board at such an important point in its development,” said Dr. Eckler. “Rezatapopt represents a differentiated approach to targeting mutant p53, with the potential to address a significant unmet need for patients with difficult-to-treat cancers. I’m excited to collaborate closely with the Board and management team to help guide the Company through this next phase of growth and unlock the potential of its transformative science.”

Dr. Eckler is a Principal at Samsara BioCapital where he leads the firm’s public equity strategy. Before joining Samsara in 2025, he held investment roles at ArrowMark Partners, and GMT Capital, and served as Vice President and Senior Biotech Analyst at RBC Capital Markets. Earlier in his career, he conducted research on the genetics of early brain development and circuit-level plasticity.

He received a B.S. in biology from the University of North Carolina at Chapel Hill and a Ph.D. in molecular biology from the University of California (UC), Santa Cruz. Dr. Eckler completed his postdoctoral work in neuroscience at UC San Diego.

About PMV Pharma

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s future plans or expectations for rezatapopt, including our ability to obtain approval as a treatment option as a monotherapy, expectations regarding timing and success of the Phase 2 portion of the current clinical trial for rezatapopt and filing of a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Company’s product candidate development activities, including the successful filing of NDAs, and planned clinical trials, the Company’s ability to execute on its strategy and operate as a clinical stage company, the potential for clinical trials of rezatapopt or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results, maintenance by the Company of ODD status and related benefits for rezatapopt, the Company’s ability to fund operations, and the impact that a global pandemic, other public health emergencies or geopolitical tensions or conflicts may have on the Company’s clinical trials, supply chain, and

operations, as well as those risks and uncertainties set forth in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2026, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026, and the Company’s other filings filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contacts

Investors Contact:

Tim Smith

Senior Vice President, Head of Corporate Development and Investor Relations

investors@pmvpharma.com

Media Contact:

Kathy Vincent

Greig Communications

kathy@greigcommunications.com

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 10.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB